A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024: Rahway, New Jersey Saturday, October ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Shawn Johnson shares daughter Drew Hazel, 4, and sons Jett James, 2, and Barrett 'Bear' Madison, 10 months, with her husband ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.